Cited by 152Glioma Diagnosis and TreatmentCancer survivorship and careOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Clinical Practice Experience With NovoTTF-100A™ System for Glioblastoma: The Patient Registry Dataset (PRiDe)

Open access

Mrugala, Maciej M., Engelhard, Herbert H., Dinh Tran, David, Kew, Yvonne, Cavaliere, Robert, Villano, John L., Annenelie Bota, Daniela, Rudnick, Jeremy, Love Sumrall, Ashley, Zhu, Jay-Jiguang, Butowski, Nicholas·2014·Seminars in Oncology

DOI 10.1053/j.seminoncol.2014.09.010

Open this paper in CoChat — free account

Abstract

Recurrent glioblastoma multiforme (GBM) is a highly aggressive cancer with poor prognosis, and an overall survival of 6 to 7 months with optimal therapies. The NovoTTF-100A™ System is a novel antimitotic cancer therapy recently approved for the treatment of recurrent GBM, based on phase III (EF-11) trial results. The Patient Registry Dataset (PRiDe) is a post-marketing registry of all recurrent GBM patients who received NovoTTF Therapy in a real-world, clinical practice setting in the United States between 2011 and 2013. Data were collected from all adult patients with recurrent GBM who began commercial NovoTTF Therapy in the United States between October 2011 and November 2013. All patients provided written consent before treatment was started. Overall survival (OS) curves were constructed for PRiDe using the Kaplan-Meier method. Median OS in PRiDe was compared for patients stratified by average daily compliance (≥75% v<75% per day) and other prognostic variables. Adverse events were also evaluated. Data from 457 recurrent GBM patients who received NovoTTF Therapy in 91 US cancer centers were analyzed. More patients in PRiDe than the EF-11 trial received NovoTTF Therapy for first recurrence (33% v 9%) and had received prior bevacizumab therapy (55.1% v 19%). Median OS was significantly longer with NovoTTF Therapy in clinical practice (PRiDe data set) than in the EF-11 trial (9.6 v 6.6 months; HR, 0.66; 95% CI, 0.05 to 0.86, P = .0003). One- and 2-year OS rates were more than double for NovoTTF Therapy patients in PRiDe than in the EF-11 trial (1-year: 44% v 20%; 2-year: 30% v 9%). First and second versus third and subsequent recurrences, high Karnofsky performance status (KPS), and no prior bevacizumab use were favorable prognostic factors. No unexpected adverse events were detected in PRiDe. As in the EF-11 trial, the most frequent adverse events were mild to moderate skin reactions associated with application of the NovoTTF Therapy transducer arrays. Results from PRiDe, together with those previously reported in the EF-11 trial, indicate that NovoTTF Therapy offers clinical benefit to patients with recurrent GBM. NovoTTF Therapy has high patient tolerability and favorable safety profile in the real-world, clinical practice setting.

Integrity signals

Registry

Crossref · 10.1053/j.seminoncol.2014.09.010

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., TAPHOORN, M. J. B., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Bélanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,980
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N. A., Nicholas, M. K., Jensen, R. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,516
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
The epidemiology of glioma in adults: a "state of the science" review
Ostrom, Q. T., Bauchet, L., Davis, F. G., Deltour, I., Fisher, J. L., Langer, C. E., Pekmezci, M., Schwartzbaum, J., Turner, M. C., Walsh, K. M., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou087 · Cited by 2,320
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M. A., Butman, J. A., Camphausen, K. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,567
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J. E., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,417
State of the Science
Riegel, B. J., Moser, D. K., Anker, S. D., Appel, L. J., Dunbar, S. B., Grady, K. L., Gurvitz, M. Z., Havranek, E. P., Lee, C. S., Lindenfeld, J. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192628 · Cited by 986
Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors
Kirson, E. D., Dbalý, V., Tovaryš, F., Vymazal, J., Soustiel, J. F., Itzhaki, A., Mordechovich, D., Steinberg-Shapira, S., Gurvich, Z., Schneiderman, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702916104 · Cited by 894
NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
Stupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.011 · Cited by 862
Self-citation

Show all 36 references

Research works printed but not linked: 1

Kirson, 2010, Modeling tumor growth kinetics and its implications for TTFields treatment planning. [abstract], Neurooncology (Meeting Abstracts), 12

Sorted by citations

Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells
Giladi, M., Schneiderman, R. S., Voloshin, T., Porat, Y., Munster, M., Blat, R., Sherbo, S., Bomzon, Z., Urman, N., Itzhaki, A., et al. (2015) · Scientific Reports · doi:10.1038/srep18046 · Cited by 327
Tumour treating fields therapy for glioblastoma: current advances and future directions
Rominiyi, O., Vanderlinden, A., Clenton, S. J., Bridgewater, C. H., Al-Tamimi, Y., & Collis, S. J. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01136-5 · Cited by 342
Treatment of Glioblastoma (GBM) with the Addition of Tumor-Treating Fields (TTF): A Review
Fabian, D., Eibl, M. D. P. G. P., Alnahhas, I., Sebastian, N., Giglio, P., Puduvalli, V. K., Gonzalez, J., & Palmer, J. D. (2019) · Cancers · doi:10.3390/cancers11020174 · Cited by 249
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial
Toms, S. A., Kim, C., Nicholas, G. A., & Ram, Z. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-03057-z · Cited by 188
Tumor treating fields: A novel treatment modality and its use in brain tumors
Hottinger, A. F., Pacheco, P., & Stupp, R. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now182 · Cited by 177
Central Nervous System Cancers, Version 1.2015
Nabors, B., Portnow, J., Ammirati, M., Baehring, J. M., Brem, H., Brown, P. D., Butowski, N. A., Chamberlain, M. C., Fenstermaker, R. A., Friedman, A. H., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0148 · Cited by 177
Self-citation
Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells
Giladi, M., Munster, M., Schneiderman, R. S., Voloshin, T., Porat, Y., Blat, R., Zielinska-Chomej, K., Hååg, P., Bomzon, Z., Kirson, E. D., et al. (2017) · Radiation Oncology · doi:10.1186/s13014-017-0941-6 · Cited by 160
Virtual Human Models for Electromagnetic Studies and Their Applications
Makarov, S. N., Noetscher, G. M., Yanamadala, J., Piazza, M. W., Louie, S., Prokop, A., Nazarian, A., & Nummenmaa, A. R. (2017) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2017.2722420 · Cited by 157
Tumor treating fields increases membrane permeability in glioblastoma cells
Chang, E., Patel, C. B., Pohling, C., Young, C., Song, J., Flores, T. A., Zeng, Y., Joubert, L.-M., Arami, H., Natarajan, A., et al. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0130-x · Cited by 137
A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling
Wenger, C., Miranda, P. C., Salvador, R., Thielscher, A., Bomzon, Z., Giladi, M., Mrugala, M. M., & Korshoej, A. R. (2018) · IEEE Reviews in Biomedical Engineering · doi:10.1109/rbme.2017.2765282 · Cited by 129
Self-citation
The electric field distribution in the brain during TTFields therapy and its dependence on tissue dielectric properties and anatomy: a computational study
Wenger, C., Salvador, R., Basser, P. J., & Miranda, P. C. (2015) · Physics in Medicine and Biology · doi:10.1088/0031-9155/60/18/7339 · Cited by 121
Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients
Mehta, M. P., Wen, P. Y., Nishikawa, R., Reardon, D. A., & Peters, K. B. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.005 · Cited by 116
Tumor Treating Fields in the Management of Patients with Malignant Gliomas
Ghiaseddin, A. P., Shin, D. H., Melnick, K. F., & Tran, D. D. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00773-5 · Cited by 106
Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future
Chen, R., Cohen, A. L., & Colman, H. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0418-0 · Cited by 104
Permeabilizing Cell Membranes with Electric Fields
Aguilar, A. A., Ho, M. C., Chang, E., Carlson, K. W., Natarajan, A., Marciano, T., Bomzon, Z., & Patel, C. B. (2021) · Cancers · doi:10.3390/cancers13092283 · Cited by 76
Improving Tumor Treating Fields Treatment Efficacy in Patients With Glioblastoma Using Personalized Array Layouts
Wenger, C., Salvador, R., Basser, P. J., & Miranda, P. C. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.11.042 · Cited by 76
Tumor-Treating Fields in Glioblastomas: Past, Present, and Future
Guo, X., Yang, X., Wu, J., Yang, H., Li, Y., Li, J., Liu, Q., Chen, W., Xing, H., Liu, P., et al. (2022) · Cancers · doi:10.3390/cancers14153669 · Cited by 75
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial
Kesari, S., Ram, Z., & on behalf of EF-14 Trial Investigators (2017) · CNS Oncology · doi:10.2217/cns-2016-0049 · Cited by 73
Impact of tumor position, conductivity distribution and tissue homogeneity on the distribution of tumor treating fields in a human brain: A computer modeling study
Korshoej, A. R., Hansen, F. L., Thielscher, A., von Öettingen, G., & Sørensen, J. C. H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179214 · Cited by 71
The Evolving Role of Tumor Treating Fields in Managing Glioblastoma
Burri, S. H., Gondi, V., Brown, P. D., & Mehta, M. P. (2017) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000395 · Cited by 75
Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma
Lacouture, M. E., Anadkat, M. J., Ballo, M. T., IWAMOTO, F. M., Jeyapalan, S. A., Rocca, R. V. L., Schwartz, M. A., Serventi, J. N., & Glas, M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01045 · Cited by 73
Electrotherapies for Glioblastoma
Jenkins, E. P. W., Finch, A., Gerigk, M., Triantis, I. F., Watts, C., & Malliaras, G. G. (2021) · Advanced Science · doi:10.1002/advs.202100978 · Cited by 70
Immunogenic cell death and its therapeutic or prognostic potential in high-grade glioma
Decraene, B., Yang, Y., Smet, F. D., Garg, A. D., Agostinis, P., & Vleeschouwer, S. D. (2022) · Genes and Immunity · doi:10.1038/s41435-021-00161-5 · Cited by 75
An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma
Swanson, K. D., Lok, E., & Wong, E. T. (2016) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-015-0606-5 · Cited by 66
Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition
Kessler, A. F., Frömbling, G. E., Gross, F., Hahn, M., Dzokou, W., Ernestus, R.-I., Löhr, M., & Hagemann, C. (2018) · Cell Death Discovery · doi:10.1038/s41420-018-0079-9 · Cited by 64
Importance of electrode position for the distribution of tumor treating fields (TTFields) in a human brain. Identification of effective layouts through systematic analysis of array positions for multiple tumor locations
Korshoej, A. R., Hansen, F. L., Mikic, N., von Öettingen, G., Sørensen, J. C. H., & Thielscher, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201957 · Cited by 62
Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice
Shi, W., Blumenthal, D. T., Oberheim Bush, N. A., Kebir, S., Lukas, R. V., Muragaki, Y., Zhu, J.-J., & Glas, M. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03540-6 · Cited by 61
Self-citation
Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma
Khagi, S., Kotecha, R. R., Gatson, N. T., Jeyapalan, S. A., Abdullah, H. I., Avgeropoulos, N. G., Batzianouli, E., Giladi, M., Lustgarten, L., & Goldlust, S. A. (2024) · The Oncologist · doi:10.1093/oncolo/oyae227 · Cited by 57
Progress and prospect in tumor treating fields treatment of glioblastoma
Liu, S., Shi, W., Zhao, Q., Zheng, Z., Liu, Z., Meng, L., Dong, L., & Jiang, X. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111810 · Cited by 62
Enhancing Predicted Efficacy of Tumor Treating Fields Therapy of Glioblastoma Using Targeted Surgical Craniectomy: A Computer Modeling Study
Korshoej, A. R., Saturnino, G. B., Rasmussen, L. K., von Öettingen, G., Sørensen, J. C. H., & Thielscher, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164051 · Cited by 54
Use of bevacizumab in recurrent glioblastoma
Ghiaseddin, A. P., & Peters, K. B. (2015) · CNS Oncology · doi:10.2217/cns.15.8 · Cited by 54
Tumor treating fields: a new approach to glioblastoma therapy
Rick, J. W., Chandra, A., & Aghi, M. K. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2768-x · Cited by 54
Contemporary use of real-world data for clinical trial conduct in the United States: a scoping review
Rogers, J. R., Lee, J., Zhou, Z., Cheung, Y. K., Hripcsak, G. M., & Weng, C. (2020) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocaa224 · Cited by 51
Tumor Treating Fields for Glioblastoma Treatment: Patient Satisfaction and Compliance With the Second-Generation Optune ® System
Kinzel, A., Ambrogi, M., Varshaver, M., & Kirson, E. D. (2019) · Clinical Medicine Insights Oncology · doi:10.1177/1179554918825449 · Cited by 48
An implantable ultrasound-powered device for the treatment of brain cancer using electromagnetic fields
Yang, Y., Hu, X., Liu, Y., Ouyang, B., Zhang, J., Jin, H., Yu, Z., Liu, R., Li, Z., Jiang, L., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm5023 · Cited by 45
Recurrent Glioblastoma—Molecular Underpinnings and Evolving Treatment Paradigms
Chang, C., Chavarro, V. S., Gerstl, J. V. E., Blitz, S. E., Spanehl, L., Dubinski, D., Valdes, P. A., Tran, L. N., Gupta, S., Esposito, L., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126733 · Cited by 45
Tumor Treating Fields Technology: Alternating Electric Field Therapy for the Treatment of Solid Tumors
Benson, L. M. (2018) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2018.03.005 · Cited by 41
The effects of alternating electric fields in glioblastoma: current evidence on therapeutic mechanisms and clinical outcomes
Rehman, A. A., Elmore, K. B., & Mattei, T. A. (2015) · Neurosurgical FOCUS · doi:10.3171/2015.1.focus14742 · Cited by 40
Acceptance and compliance of TTFields treatment among high grade glioma patients
Onken, J., Staub‐Bartelt, F., Vajkoczy, P., & Misch, M. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2858-9 · Cited by 38
Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial
Ram, Z., Kim, C., Hottinger, A. F., Idbaïh, A., Nicholas, G. A., & Zhu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.671972 · Cited by 37
Self-citation
OptimalTTF-1: Enhancing tumor treating fields therapy with skull remodeling surgery. A clinical phase I trial in adult recurrent glioblastoma
Korshoej, A. R., Lukacova, S., Lassen–Ramshad, Y., Rahbek, C., Severinsen, K. E., Guldberg, T. L., Mikic, N., Jensen, M. H., Cortnum, S., von Öettingen, G., et al. (2020) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaa121 · Cited by 36
An Evidence-Based Review of Alternating Electric Fields Therapy for Malignant Gliomas
Wong, E. T., Lok, E., & Swanson, K. D. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0353-5 · Cited by 35
Tumor-Treating Fields for the treatment of glioblastoma: a systematic review and meta-analysis
Regev, O., Merkin, V., Blumenthal, D. T., Melamed, I., & Kaisman‐Elbaz, T. (2021) · Neuro-Oncology Practice · doi:10.1093/nop/npab026 · Cited by 36
Pulsed Electric Fields in Oncology: A Snapshot of Current Clinical Practices and Research Directions from the 4th World Congress of Electroporation
Campana, L. G., DAUD, A. I., Lancellotti, F., Arroyo, J. P., Davalos, R. V., Prata, C. D., & Gehl, J. (2023) · Cancers · doi:10.3390/cancers15133340 · Cited by 36
In Vivo Safety of Tumor Treating Fields (TTFields) Applied to the Torso
Blatt, R., Davidi, S., Munster, M., Shteingauz, A., Cahal, S., Zeidan, A., Marciano, T., Bomzon, Z., Haber, A., Giladi, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.670809 · Cited by 32
Overexpressed miR-183 promoted glioblastoma radioresistance via down-regulating LRIG1
Fan, H., Yuan, R., Cheng, S., Xiong, K., Xingen, Z., & Zhang, Y. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.11.050 · Cited by 31
Medical Device Advances in the Treatment of Glioblastoma
Foo, C. Y., Munir, N., Kumaria, A., Akhtar, Q., Bullock, C. J., Narayanan, A., & Fu, R. Z. (2022) · Cancers · doi:10.3390/cancers14215341 · Cited by 32
Skin toxicities associated with tumor treating fields: case based review
Lukas, R. V., Julian, K. L., Wong, E. T., & Villano, J. L. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2612-8 · Cited by 31
Self-citation
Anti-cancer mechanisms of action of therapeutic alternating electric fields (tumor treating fields [TTFields])
Shams, S., & Patel, C. B. (2022) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjac047 · Cited by 34
Tumor treating fields therapy device for glioblastoma: physics and clinical practice considerations
Lok, E., Swanson, K. D., & Wong, E. T. (2015) · Expert Review of Medical Devices · doi:10.1586/17434440.2015.1086641 · Cited by 28
Tumor Treating Fields Concomitant with Sorafenib in Advanced Hepatocellular Cancer: Results of the HEPANOVA Phase II Study
Gkika, E., Grosu, A., Macarulla, T. M., Gracián, A. C., Brunner, T. B., Schultheiß, M., Pazgan−Simon, M., Seufferlein, T. T. W., & Touchefeu, Y. (2022) · Cancers · doi:10.3390/cancers14061568 · Cited by 31
Alternating Electric Fields for the Treatment of Glioblastoma
Sampson, J. H. (2015) · JAMA · doi:10.1001/jama.2015.16701 · Cited by 29
Boron Neutron Capture Therapy Combined with Early Successive Bevacizumab Treatments for Recurrent Malignant Gliomas – A Pilot Study
Shiba, H., Takeuchi, K., Hiramatsu, R., Furuse, M., Nonoguchi, N., Kawabata, S., Kuroiwa, T., Kondo, N., Sakurai, Y., Suzuki, M., et al. (2018) · Neurologia medico-chirurgica · doi:10.2176/nmc.oa.2018-0111 · Cited by 28
How We Treat Recurrent Glioblastoma Today and Current Evidence
Barbosa, C. C., & Marques, D. F. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0834-y · Cited by 27
Advances in radiotherapy and comprehensive treatment of high-grade glioma: immunotherapy and tumor-treating fields
Liu, S., Zhao, Q., Shi, W., Zheng, Z., Liu, Z., Meng, L., Dong, L., & Jiang, X. M. (2020) · Journal of Cancer · doi:10.7150/jca.51107 · Cited by 29
Current and promising treatment strategies in glioma
Śledzińska, P., Bebyn, M. G., Furtak, J., Koper, A., & Koper, K. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0060 · Cited by 28
Tumor Treating Fields Combine with Temozolomide for Newly Diagnosed Glioblastoma: A Retrospective Analysis of Chinese Patients in a Single Center
Chen, C., Xu, H., Song, K., Zhang, Y., Zhang, J., Wang, Y., Sheng, X., Chen, L., & Qin, Z. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195855 · Cited by 25
Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study
Nishikawa, R., Yamasaki, F., Arakawa, Y., Muragaki, Y., Narita, Y., Tanaka, S., Yamaguchi, S., Mukasa, A., & Kanamori, M. (2023) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyad001 · Cited by 25
A systematic review of tumor treating fields therapy for high-grade gliomas
Shah, P. P., White, T., Khalafallah, A. M., Romo, C. G., Price, C. L., & Mukherjee, D. R. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03563-z · Cited by 23
Clinical Efficacy of Tumor Treating Fields for Newly Diagnosed Glioblastoma
Liu, Y., Strawderman, M. S., Warren, K., Richardson, M., Serventi, J. N., Mohile, N. A., Milano, M. T., & Walter, K. A. (2020) · Anticancer Research · doi:10.21873/anticanres.14597 · Cited by 22
Effectiveness and safety of tumor-treating fields therapy for glioblastoma: A single-center study in a Chinese cohort
She, L., Gong, X., Su, L., & Liu, C. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2022.1042888 · Cited by 23
Computational Trials: Unraveling Motility Phenotypes, Progression Patterns, and Treatment Options for Glioblastoma Multiforme
Raman, F., Scribner, E. Y., Saut, O., Wenger, C., Colin, T., & Fathallah‐Shaykh, H. M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146617 · Cited by 24
Tumor Treating Fields (TTFields) therapy vs physicians’ choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19)
Zhu, J., Goldlust, S. A., Kleinberg, L. R., Honnorat, J., Bush, N. A. O., & Ram, Z. (2022) · Discover Oncology · doi:10.1007/s12672-022-00555-5 · Cited by 23
Self-citation
Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series
Ansstas, G., & Tran, D. D. (2016) · Case Reports in Neurology · doi:10.1159/000442196 · Cited by 21
Current clinical management of patients with glioblastoma
Lowe, S. R., Bhat, K., & Olar, A. (2019) · Cancer Reports · doi:10.1002/cnr2.1216 · Cited by 20
Study protocol for OptimalTTF-2: enhancing Tumor Treating Fields with skull remodeling surgery for first recurrence glioblastoma: a phase 2, multi-center, randomized, prospective, interventional trial
Mikic, N., Poulsen, F. R., Kristoffersen, K. B., Laursen, R. J., Guldberg, T. L., Skjøth‐Rasmussen, J., Wong, E. T., Møller, S., Dahlrot, R. H., Sørensen, J. C. H., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08709-4 · Cited by 20
The Routine Application of Tumor-Treating Fields in the Treatment of Glioblastoma WHO° IV
Krigers, A., Pinggera, D., Demetz, M., Kornberger, L.-M., Kerschbaumer, J., Thomé, C., & Freyschlag, C. F. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.900377 · Cited by 20
Temperature and Impedance Variations During Tumor Treating Fields (TTFields) Treatment
Gentilal, N., Abend, E., Naveh, A., Marciano, T., Balin, I., Telepinsky, Y., & Miranda, P. C. (2022) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.931818 · Cited by 20
Novel therapeutic strategies in glioma targeting glutamatergic neurotransmission
Kumaria, A., & Ashkan, K. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148515 · Cited by 20
Tumor treating fields in neuro-oncology: integration of alternating electric fields therapy into promising treatment strategies
Berger, T. R., & Wong, E. T. (2020) · Chinese Clinical Oncology · doi:10.21037/cco.2020.02.04 · Cited by 18
Empowering rapid diagnosis and treatment of glioblastoma with biofunctionalized carbon quantum dots: a review
Kazemi, K., Amini, A., Omidifar, N., Aghaabdollahian, S., Raee, M. J., & Gholami, A. (2025) · Cancer Nanotechnology · doi:10.1186/s12645-025-00317-2 · Cited by 18
Skull modulated strategies to intensify tumor treating fields on brain tumor: a finite element study
Yang, X., Liu, P., Xing, H., Wen, X., Wang, Y., Hu, C., Li, L., & Ma, W. (2022) · Biomechanics and Modeling in Mechanobiology · doi:10.1007/s10237-022-01580-7 · Cited by 17
Efficacy of tumour-treating fields therapy in recurrent glioblastoma: A narrative review of current evidence
Olatunji, G. D., Aderinto, N., Oluwakorede, A. T., Kokori, E., Akinmoju, O. D., Yusuf, I. A., Olusakin, T. C., & Muzammil, M. A. (2023) · Medicine · doi:10.1097/md.0000000000036421 · Cited by 17
Global post‑marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011–2022
Mrugała, M. M., Shi, W., Iwomoto, F., Lukas, R. V., Palmer, J. D., Suh, J. H., & Glas, M. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04682-7 · Cited by 21
First report of tumor treating fields use in combination with bevacizumab in a pediatric patient: a case report
O’Connell, D., Shen, V., Loudon, W. G., & Bota, D. A. (2016) · CNS Oncology · doi:10.2217/cns-2016-0018 · Cited by 17
Tumor-Treating Fields Therapy for Pediatric Brain Tumors
Makimoto, A., Nishikawa, R., Terashima, K., Kurihara, J., Fujisaki, H., Ihara, S., Morikawa, Y., & Yuza, Y. (2021) · Neurology International · doi:10.3390/neurolint13020015 · Cited by 19
Tumor Treating Fields in Neuro-Oncological Practice
Mrugała, M. M., Ruzevick, J., Złomańczuk, P., & Lukas, R. V. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0611-8 · Cited by 16
Feasibility of Tumor Treating Fields with Pemetrexed and Platinum-Based Chemotherapy for Unresectable Malignant Pleural Mesothelioma: Single-Center, Real-World Data
Kütük, T., Appel, H. R., Avendano, M. C., Albrecht, F., Kaywin, P., Ramos, S., Suarez-Murias, M., Mehta, M. P., & Kotecha, R. R. (2022) · Cancers · doi:10.3390/cancers14082020 · Cited by 16
Tumor-treating fields as a proton beam-sensitizer for glioblastoma therapy.
Lee, W. S., Seo, S., Chung, H. K., Park, J. W., Kim, J.-K., & Kim, E. H. (2021) · PubMed Central · Cited by 14
Efficacy and selectivity of tumor-treating field therapy for triple-negative breast cancer cells via in-house delivery device
Smothers, A. R., Henderson, J. R., O’Connell, J. J., Stenbeck, J. M., Dean, D., Harvey, T. G., & Booth, B. W. (2023) · Discover Oncology · doi:10.1007/s12672-023-00647-w · Cited by 15
Tumor treating fields: narrative review of a promising treatment modality for cancer
Kütük, T., Atak, E., Rosa, A. L., Kotecha, R. R., Mehta, M. P., & Chuong, M. D. (2023) · Chinese Clinical Oncology · doi:10.21037/cco-23-82 · Cited by 13
Acoustoelectric materials & devices in biomedicine
Zhang, X., Zhang, Y., Zhang, J., Shang, J., Lin, L., Liu, Q., & An, Q. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.149314 · Cited by 13
Safety of Tumor Treating Fields (TTFields) therapy in pediatric patients with malignant brain tumors: Post-marketing surveillance data
Goldman, S., Margol, A., Hwang, E. I., Tanaka, K., Suchorska, B., Crawford, J. R., & Kesari, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.958637 · Cited by 13
Chronic inflammation: is it the driver or is it paving the road for malignant transformation?
Afrasiabi, K., Zhou, Y., & Fleischman, A. G. (2015) · Genes & Cancer · doi:10.18632/genesandcancer.64 · Cited by 12
Optune®: Practical Nursing Applications
Murphy, J., Bowers, M. E., & Barron, L. (2016) · Clinical journal of oncology nursing · doi:10.1188/16.cjon.s1.14-19 · Cited by 12
Tumor-treating fields as a fourth treating modality for glioblastoma: a meta-analysis
Magouliotis, D. E., Asprodini, E. K., Svokos, K. A., Tasiopoulou, V. S., Svokos, A. A., & Toms, S. A. (2018) · Acta Neurochirurgica · doi:10.1007/s00701-018-3536-6 · Cited by 12
The safety profile of Tumor Treating Fields (TTFields) therapy in glioblastoma patients with ventriculoperitoneal shunts
Oberheim-Bush, N. A., Shi, W., McDermott, M. W., Grote, A., Stindl, J., & Lustgarten, L. (2022) · Journal of Neuro-Oncology · doi:10.1007/s11060-022-04033-4 · Cited by 13
Tumor treating fields
Taillibert, S., Rhun, É. L., & Chamberlain, M. C. (2015) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000250 · Cited by 11
Amino Acid PET Imaging of the Early Metabolic Response During Tumor-Treating Fields (TTFields) Therapy in Recurrent Glioblastoma
Bosnyák, E., Barger, G. R., Michelhaugh, S. K., Robinette, N. L., Amit-Yousif, A. J., Mittal, S., & Juhász, C. (2017) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001942 · Cited by 11
Water-Content Electrical Property Tomography (wEPT) for Mapping Brain Tissue Conductivity in the 200–1000 kHz Range: Results of an Animal Study
Wenger, C., Hershkovich, H. S., Tempel-Brami, C., Giladi, M., & Bomzon, Z. (2019) · Springer eBooks · doi:10.1007/978-3-030-21293-3_20 · Cited by 11
Observations on the anti-glioma potential of electrical fields: is there a role for surgical neuromodulation?
Kumaria, A. (2021) · British Journal of Neurosurgery · doi:10.1080/02688697.2021.1886242 · Cited by 11
Dexamethasone and compliance affect TTFields efficacy to glioblastoma patients: a systematic review and meta-analysis
Li, S., Dong, J., Wang, X., Meng, X., Jiang, C., & Cai, J. (2022) · Chinese Neurosurgical Journal · doi:10.1186/s41016-022-00294-0 · Cited by 11
Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas
Szász, A. M., Arrojo, E. E., Fiorentini, G., Herold, M., Herold, Z., Sarti, D., & Dank, M. (2023) · Cancers · doi:10.3390/cancers15030880 · Cited by 10
Tumor treating fields in glioblastoma: long-term treatment and high compliance as favorable prognostic factors
Wang, J., Du, Q., Chen, J., Liu, J., Gu, Z., Wang, X., Zhang, A., Gao, S., Shao, A., Zhang, J., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1345190 · Cited by 10
Tumor Treating Fields and Combination Therapy in Management of Brain Oncology
Liu, R. N., Huang, J. H., Qi, X., Pan, Y., Wu, E., & Nizamutdinov, D. (2025) · Cancers · doi:10.3390/cancers17071211 · Cited by 10
Efficacy and safety of tumor-treating fields in recurrent glioblastoma: a systematic review and meta-analysis
Li, X., Jia, Z., & Yan, Y. (2022) · Acta Neurochirurgica · doi:10.1007/s00701-022-05192-z · Cited by 10
From imaging to biology of glioblastoma: new clinical oncology perspectives to the problem of local recurrence
Zygogianni, A. G., Protopapa, M., Kougioumtzopoulou, A., Simopoulou, F., Nikoloudi, S., & Kouloulias, V. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1831-6 · Cited by 10
Optimization of tumor-treating field therapy for triple-negative breast cancer cells in vitro via frequency modulation
Smothers, A. R., Henderson, J. R., O’Connell, J. J., Stenbeck, J. M., Dean, D., & Booth, B. W. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02959-x · Cited by 9
Tumor-treating fields in combination with sorafenib curtails the growth of colorectal carcinoma by inactivating AKT/STAT3 signaling
Kim, E. H., Lee, W. S., & Oh, H. K. (2022) · Translational Cancer Research · doi:10.21037/tcr-21-1853 · Cited by 9
An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma
Barkhoudarian, G., Badruddoja, M., Blondin, N. A., Chowdhary, S. A., Cobbs, C., Duic, J. P., Flores, J. P., Fonkem, E., McClay, E. F., Nabors, B., et al. (2023) · CNS Oncology · doi:10.2217/cns-2022-0016 · Cited by 9

Authors: Mrugala, M. M., Engelhard, H. H., Dinh Tran, D., Kew, Y., Cavaliere, R., Villano, J. L., Annenelie Bota, D., Rudnick, J., Love Sumrall, A., Zhu, J.-J., & Butowski, N.
Affiliations: University of Illinois Hospital & Health Sciences System (US)
Houston Methodist (US)
The Ohio State University (US)
University of Illinois Chicago (US)
Cedars-Sinai Medical Center (US)
The University of Texas Health Science Center at Houston (US)
University of California, San Francisco (US)
ORCID: Engelhard, Herbert H.
Cavaliere, Robert
Villano, John L.
Rudnick, Jeremy
Zhu, Jay-Jiguang
Butowski, Nicholas
Venue: Seminars in Oncology
Publisher: Elsevier BV
Published: 2014-10
Volume: 41
Pages: S4-S13
ISSN: 0093-7754 (ISSN-L)
DOI: 10.1053/j.seminoncol.2014.09.010
OpenAlex: W1994913111
Cited by: 152
References: 36
Citations by year: 2026: 8 · 2025: 11 · 2024: 12 · 2023: 14 · 2022: 25 · 2021: 12 · 2020: 11 · 2019: 8 · 2018: 13 · 2017: 12 · 2016: 13 · 2015: 13
FWCI: 6.36
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 20 d)
Locations: Seminars in Oncology (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
eScholarship (California Digital Library) (submittedVersion)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Cancer survivorship and care
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: overall survival, medication adherence, bevacizumab, prognostic factors, Karnofsky performance status, adverse events, skin reactions, real-world clinical practice, first recurrence
MeSH terms: Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Combined Modality Therapy, Electric Stimulation Therapy, Female, Follow-Up Studies, Glioblastoma, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Practice Patterns, Physicians', Prognosis, Registries, Survival Rate, Clinical Trials, Phase III as Topic, Young Adult, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clinical Practice Experience With NovoTTF-100A™ System for Glioblastoma: The Patient Registry Dataset (PRiDe)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks